Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | terminated | Phase 2 | 29 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00002934 | Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ | terminated | Phase 2 | 711 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT04305236 |
| Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer |
| terminated |
| Phase 2 |
| 1 |
| University of California, IrvineOTHER |
| 1 |
| Jun 6, 2023 |
| clinicaltrials |
| NCT00074269 | Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer | terminated | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT00597597 | Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer | terminated | Phase 2 | 11 | Rush University Medical CenterOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT01147016 | Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery | terminated | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04189263 | BREADS: Breast Adjuvant Diet Study | terminated | Phase 2 | 6 | Farin AmersiOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | terminated | Phase 2 | 11 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Apr 10, 2023 | clinicaltrials |
| NCT00323063 | Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer | terminated | Phase 2 | 49 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03354611 | Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging | terminated | Phase 2 / Phase 3 | 21 | Koning CorporationINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03367689 | A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent(NOBROLA) | terminated | Phase 2 | 7 | MedSIROTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03931551 | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer(OPHELIA) | terminated | Phase 2 | 5 | MedSIROTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT01022138 | Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer | terminated | Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02229149 | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | terminated | Phase 2 | 33 | US Oncology ResearchINDUSTRY | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03386162 | SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer(SAFIR-PI3K) | terminated | Phase 2 | 31 | UNICANCEROTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity | terminated | Phase 2 | 148 | Washington University School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04142060 | Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC(ARIANNA) | terminated | Phase 2 | 34 | SOLTI Breast Cancer Research GroupOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04460430 | Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer(NEREA) | terminated | Phase 2 | 12 | SOLTI Breast Cancer Research GroupOTHER | 2 | Oct 25, 2022 | clinicaltrials |
| NCT02113553 | Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve | terminated | Phase 2 | 45 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) | terminated | Phase 2 / Phase 3 | 27 | ERYtech PharmaINDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT03147040 | AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer(GELATO) | terminated | Phase 2 | 23 | The Netherlands Cancer InstituteOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT02826512 | A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients | terminated | Phase 2 | 9 | The Netherlands Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT05063604 | Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression(CAMAD) | terminated | Phase 2 | 40 | Hospital Universitari de BellvitgeOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT03874325 | Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT02000596 | 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. | terminated | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT03787303 | Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma(B-TREUH) | terminated | Phase 2 | 7 | Aultman Health FoundationOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery(0927GCC) | terminated | Phase 2 | 5 | University of Maryland, BaltimoreOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | terminated | Phase 2 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02269670 | Phase II Study of Everolimus Beyond Progression | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | terminated | Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 8 | Mar 23, 2022 | clinicaltrials |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01036113 | A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer(PEG-SN38) | terminated | Phase 2 | 160 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02236572 | Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | terminated | Phase 2 | 17 | Yale UniversityOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT00925652 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer(ABCDE) | terminated | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | terminated | Phase 2 | 29 | BerGenBio ASAINDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT04298918 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 8, 2021 | clinicaltrials |
| NCT01934335 | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | terminated | Phase 2 | 12 | Ronald WeigelOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT00110136 | St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer | terminated | Phase 2 | 9 | Wake Forest University Health SciencesOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | terminated | Phase 2 | 78 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02833766 | Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer | terminated | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02907918 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer(PALTAN) | terminated | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Sep 29, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2023source: clinicaltrials